Topic: acute lymphoblastic leukemia
The AACR conference featured data on promising new approaches to CAR-T treatments and stimulating cancer-killing immune cells.
Gilead and its $12 billion biotech buy Kite Pharma have teamed up with Pfizer to work on a Yescarta-utomilumab combo test in certain blood cancers.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
The filing positions one of 2017’s star performers on European exchanges to start trading in the U.S. and fund a phase 3 pancreatic cancer trial.
Juno Therapeutics has halted development of its lead CAR-T therapy months after patient deaths hindered the odds of success.
Pfizer said the FDA has given its experimental leukemia med inotuzumab ozogamicin a priority review as it gets to work on assessing the medication for approval.
Erytech has withdrawn an application for approval of its tumor starvation drug in Europe after the regulator demanded more data.